Literature DB >> 15158363

Agonist-induced regulation and trafficking of kappa opioid receptors.

Lee-Yuan Liu-Chen1.   

Abstract

Chronic or repeated administration of kappa opioid agonists leads to tolerance to the subsequent drug administration. The mechanisms underlying tolerance are complex and changes at the receptor level contribute in part to the development of tolerance. This review focuses on agonist-induced phosphorylation, desensitization, internalization and down-regulation of the kappa opioid receptor. In vivo studies on the rat and guinea pig brains are reviewed, followed by in vitro investigations on cells and tissues endogenously expressing the kappa opioid receptor. The bulk of the article describes the studies performed after cloning of the opioid receptors on regulation and trafficking of the kappa opioid receptors (KORs) expressed in various cell systems. Topics reviewed and discussed include biochemical mechanisms of desensitization, internalization and down-regulation, differences in the regulation of the rat and the human kappa opioid receptors (rKOR and hKOR, respectively) and the structural basis for the species variations, differential abilities of agonists in inducing regulation of the hKOR, the relationship (or the lack thereof) of KOR internalization to activation of p42/p44 mitogen-activated kinase and to adenylyl cyclase superactivation, the role of the PDZ domain-containing protein NHERF-1/EBP50 in the trafficking of the hKOR and the relationship between receptor phosphorylation and tolerance development in mice. There are still questions remained to be answered. Among the issues to be resolved are the signals that direct the sorting of internalized hKORs to the recycling and degradation pathways, the recycling pathway(s) of the internalized hKOR, the molecular bases of differential regulation of the KORs by agonists and the occurrence of agonist-induced KOR internalization occur in vivo and, if so, its role in tolerance and dependence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158363     DOI: 10.1016/j.lfs.2003.10.041

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  58 in total

1.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 4.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 5.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

6.  Effect of adenoviral delivery of prodynorphin gene on experimental inflammatory pain induced by formalin in rats.

Authors:  Xionggang Chen; Tingting Wang; Caizhu Lin; Baihong Chen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

7.  Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens.

Authors:  Yan-fang Xia; Li He; Jennifer L Whistler; Gregory O Hjelmstad
Journal:  Neuropsychopharmacology       Date:  2007-06-06       Impact factor: 7.853

8.  Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.

Authors:  Heng Xu; Xiaoying Wang; John S Partilla; Kristen Bishop-Mathis; Tova S Benaderet; Christina M Dersch; Denise S Simpson; Thomas E Prisinzano; Richard B Rothman
Journal:  Brain Res Bull       Date:  2008-06-04       Impact factor: 4.077

Review 9.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

10.  Dynorphin inhibits basal forebrain cholinergic neurons by pre- and postsynaptic mechanisms.

Authors:  L L Ferrari; L J Agostinelli; M J Krashes; B B Lowell; T E Scammell; E Arrigoni
Journal:  J Physiol       Date:  2016-01-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.